What is Fab'entech?
Fab'entech is a specialized biotechnology firm dedicated to the production of emergency medical treatments designed to combat bioterrorism and pandemic-level pathogens. At the core of its operations is the FabShield technology platform, which utilizes highly purified polyclonal antibody fragments to neutralize viruses and toxins with high specificity. By bridging the gap between laboratory innovation and public health readiness, Fab'entech serves as a vital component in the infrastructure required to manage large-scale biological crises. The company's market position is defined by its ability to provide rapid-response solutions for lethal biological agents, making it a key player in the intersection of pharmaceutical development and national security.
How much funding has Fab'entech raised?
Fab'entech has raised a total of $6.8M across 1 funding round:
Unspecified
$6.8M
Unspecified (2014): $6.8M with participation from Auriga Partners, Rhu00f4ne-Alpes Cru00e9ation, and Sigma Gestion
Key Investors in Fab'entech
Auriga Partners
A venture capital firm focused on supporting innovative technology and life science companies through strategic growth capital.
Rhone-Alpes Creation
A French venture capital and private equity firm specializing in the development of small and medium-sized enterprises within the Auvergne-Rhone-Alpes region.
Sigma Gestion
An investment management firm approved by the Financial Markets Authority that facilitates capital allocation into promising French businesses through specialized investment funds.
What's next for Fab'entech?
Looking ahead, the capital injection will likely be directed toward scaling the manufacturing capabilities of the FabShield platform and expanding the company's clinical pipeline. As the global landscape for infectious disease management evolves, Fab'entech is expected to deepen its collaboration with public health agencies to refine its response protocols. The strategic focus will remain on enhancing the efficacy of its antibody fragments against emerging threats, thereby strengthening its competitive advantage in the biodefense market. Future growth will be contingent upon the successful navigation of regulatory pathways and the continued validation of its platform in real-world emergency scenarios.
See full Fab'entech company page
